Navigation Links
Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
Date:5/29/2012

WALTHAM, Mass., May 29, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a late-stage oncology company, announced today that updated results from ENCORE 301, a randomized, placebo-controlled phase 2 study of exemestane with and without entinostat in estrogen receptor positive metastatic breast cancer demonstrated improvement in overall survival for patients treated with exemestane plus entinostat. At median follow up of 25 months, treatment with the combination resulted in an 8.3 months improvement in overall survival (an exploratory endpoint) corresponding to a 41% reduction in the risk of dying (p = 0.04). Updated safety and efficacy results from the trial will be presented in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL on Saturday, June 2, 2012.   

Previously reported results indicated the study met the designated primary endpoint of progression-free survival (PFS) (4.28 versus 2.27 months, respectively; hazard ratio (HR = 0.73; p=0.06).  Additionally, in the subset of patients assessed for the pharmacodynamic marker of protein lysine acetylation in peripheral blood cells, acetylation in entinostat-treated patients was associated with prolonged progression-free survival to over six months across all peripheral mononuclear cell types analyzed.                 

"Entinostat combined with exemestane extends the lives of post-menopausal women with estrogen-receptor positive MBC as compared to those women that received exemestane combined with placebo and ongoing analyses of the data has not identified any contributing factors beyond the potential contribution of entinostat to account for the extended
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
4. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
5. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
6. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
7. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
8. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
11. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 Egalet Corporation (Nasdaq: ... company focused on developing, manufacturing and marketing innovative ... previously announced underwritten public offering of 7,666,667 shares ... price of $11.25 per share. The shares of ... issued upon the exercise in full by the ...
(Date:7/31/2015)... , July 31, 2015 According ... Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry ... Weighing) - Global Analysis & Forecast to 2019", published ... pegged at $911.1 Million 2014 and is estimated to ... CAGR of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 ... announced it has signed a definitive agreement ... provider of non-invasive ventilation and sleep-disordered breathing ... strong clinical, innovation and market reputation in China, combined with ResMed,s global leadership ... of people in China ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Japan, June 23 Although previous studies,suggest that ... of the eye in children with progressing myopia, ... Using a rigorous study design,and precise optical measuring ... Madrid are undertaking the Myopia Control with,Orthokeratology contact ...
... According to new data from,PAREXEL International Corporation (Nasdaq: ... the number of new,industry-sponsored clinical trial initiations, or ... in 2007. PAREXEL,s analysis shows that the,biopharmaceutical industry ... support of new clinical studies for drugs in,2007, ...
Cached Medicine Technology:Menicon Undertakes With the Novovision Clinic a Paediatric Myopia Control Clinical Trial 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 3PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 4PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 5
(Date:7/31/2015)... ... July 31, 2015 , ... The Radiology Business Management ... MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol Hill” on ... of the Congressional Health Caucus, Rep. Burgess has a special understanding of the real ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... “ Crack’em ... the latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert ... tool helps chefs make less mess while cooking. , Cooking can be a very ...
(Date:7/31/2015)... Louis, MO (PRWEB) , ... July 31, 2015 , ... ... currently underway in U.S. District Court in the Northern District of Illinois, Androgel testosterone ... On Monday, July 20, a docket entry was made recording the minutes of the ...
(Date:7/31/2015)... ... ... Seals Southern Georgia’s Heels & Wheels Duathlon & Triathlon will be held Saturday, August 22nd ... duathlon is a 2 mile run, 13 mile bike ride, and a 3 mile run. ... and a 3 mile run. Heels & Wheels is sponsored by Mayo Clinic System ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions ... recent implementation of Microsoft Dynamics GP for a senior living facility in Maine. ... supporting senior living communities in 16 states. This further expansion was again a ...
Breaking Medicine News(10 mins):Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Make Less Mess while Cooking with Crack’em 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2
... ... state of today,s global biopharmaceutical environment. , ... Horsham, PA, USA (Vocus) June 5, 2009 -- ... biopharmaceutical industry,s largest and longest running global, multidisciplinary conference featuring sessions and preconference tutorials ...
... Conference Components , , BUFFALO, N.Y., June 5, ... 2009 Annual Conference will be held June 7-11 at ... This year,s conference will focus on priority public health ... A. , , "The 2009 conference theme, ,Evidence-based ...
... (June 4, 2009) -- For patients with the most common ... protease inhibitor called telaprevir to the current standard therapy can ... it in half the time of standard therapy alone. ... Duke Clinical Research Institute (DCRI) and 36 other sites, including ...
... , WASHINGTON, June 5 The American Society of ... its 2009 Minority Medical Student Award Program (MMSAP), which ... hematology research. Under the program, each award recipient will ... career development mentor, travel stipends to attend the ASH ...
... all patients who undergo myocardial infarction are experiencing onerous fatigue ... fatigued are those who perceive the infarction as a sign ... to control, and those who believe that the illness has ... of a thesis presented at the Sahlgrenska Academy, University of ...
... /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (NASD OTC Bulletin ... the Fifth Annual Noble Financial Equity Conference at 9:15 ... Seminole Hard Rock Hotel in Hollywood, FL. Robert ... give a presentation regarding NeoGenomics, market positioning, financial performance, ...
Cached Medicine News:Health News:DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza 2Health News:DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza 3Health News:Council of State and Territorial Epidemiologists Annual Conference Begins June 7 in Buffalo, NY 2Health News:Council of State and Territorial Epidemiologists Annual Conference Begins June 7 in Buffalo, NY 3Health News:NEJM study points to new era in hepatitis C treatment 2Health News:NEJM study points to new era in hepatitis C treatment 3Health News:Minority Medical Students Receive Support to Pursue Hematology Research 2Health News:Minority Medical Students Receive Support to Pursue Hematology Research 3Health News:Fatigue common after myocardial infarction 2Health News:NeoGenomics to Present at Noble Financial's 5th Annual Equity Conference on Monday, June 8th 2
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
... Bariatric Knee Immobilizer is made of lightweight ... a breathable foam material that wicks moisture ... posterior aspect of the splint is uniquely ... The loop and lock closure straps allow ...
... brushed nylon, laminated to breathable foam. Three ... strap. Velcro straps with loop closures. Lightweight ... lateral stays., ,Available with optional hot ... Pad helps defeat the pain cycle by ...
... supports are a convenient, reusable, patient-friendly ... for common orthopedic conditions/instabilities. These products ... compression and lateral to medial influence ... the skin and soft tissue structures. ...
Medicine Products: